Simplify Logo
Johnson & Johnson

Johnson & Johnson

Global healthcare company offering pharma, devices.

Associate Dir. Cross TA Risk Management

Full-TimeDeadline 9/29/26
$122k - $212.8k/yr

+ Long-term incentive program

Senior, Expert
Bachelor's
Horsham, PA, USA+3 more

More locations: Spring House, PA, USA | Raritan, NJ, USA | Hopewell Township, NJ, USA

Hybrid

Hybrid work is required; travel up to 10%, primarily domestic with some international travel.

About the job

Requirements
  • A minimum of a Bachelor's degree in a scientific, medical, or related discipline is required.
  • A minimum of 8 years working in the healthcare industry, including the pharmaceutical industry, contract research organization, and/or healthcare or hospital system, is required.
  • Proven strong Good Clinical Practice Quality and/or clinical trials experience is required.
  • Excellent interpersonal, oral, and written communication skills are required to collaborate effectively in a cross-functional team environment.
  • Flexibility to respond to changing business needs is required.
  • Ability to operate in culturally diverse styles and business approaches by understanding regional and global business structures is required.
  • Proficiency in Microsoft Office applications is required.
  • Experience with fundamentals of clinical trial risk management is required.
  • Experience working to International Council for Harmonisation guidelines is required.
  • Health Authority Inspection experience, including FDA, EMA, and other inspectorates, is required.
  • Proficiency in speaking and writing English is required.
Responsibilities
  • Participate actively and independently in all study activities, identify and assess key risks in clinical protocol and study set-up, and advise clinical team members on mitigation strategies for complex clinical trials, compounds, and programs.
  • Lead regular reviews of risk areas with Risk Owners to evaluate mitigation progress and identify new risks or additional mitigation needs.
  • Maintain Clinical Quality Plans in the quality repository to facilitate regular progress reviews of quality support services, risks, and mitigations.
  • Drive quality risk-monitoring reviews independently and coach others on risk-monitoring and mitigation reviews.
  • Communicate and facilitate risk updates to R&D colleagues through Quality Working Groups and Governance Fora.
  • Highlight new potential systemic risks to R&D Quality Clinical Risk Management leadership.
  • Develop and ensure consistent interpretation of issues requiring quality investigations.
  • Provide guidance for significant quality issues under corporate standards and escalate them to senior R&D management.
  • Advise on the development and implementation of Corrective and Preventive Action Plans and Effectiveness Checks.
  • Drive ongoing inspection-readiness activities, including developing inspection narratives, preparing sites of interest, supporting pre-inspection visits, ensuring key documents and records are available, and coordinating mock inspections with Regulatory Compliance teams.
  • Support Investigator, Sponsor-Monitor, and third-party inspections, including post-inspection support.
  • Provide independent advice on research quality and compliance questions in collaboration with Quality Professionals and Subject Matter Experts.
  • Participate in Clinical Risk Management, cross-R&D quality, cross-functional, and cross-sector working groups to develop or refine processes, tools, and systems.
  • Provide training and coaching to peers and new employees as needed.
Desired Qualifications
  • Knowledge of Good Manufacturing Practice, Good Laboratory Practice, and/or Good Pharmacovigilance Practice.
  • Strong project planning and project management skills.
  • Experience managing escalations and providing Corrective and Preventive Action support or advisement.
  • Experience with data analytics and/or data visualization tools such as Tableau, Spotfire, or related tools.
  • Experience with Data Science and Digital Health, including Real World Evidence and Real World Disease.

About the company

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • J&J raised 2026 sales guidance to $101.1 billion after July 15, 2026 results.
  • TREMFYA delivered 71% growth in Q2 2026 and its first $2 billion quarter.
  • Apollo’s September 2026 interest in DePuy Synthes validates a near-$20 billion asset value.

What critics are saying

  • Talc litigation persists; Reuters reported a February 13, 2026 Pennsylvania loss and September 2026 settlement pressure.
  • DePuy Synthes talks with Apollo on September 11, 2026 expose $9.3 billion MedTech revenue to breakup risk.
  • STELARA’s biosimilar erosion still drags growth; another pipeline miss would expose J&J’s valuation.

What makes Johnson & Johnson unique

  • J&J’s 2025 revenue reached $94.2 billion across pharmaceuticals, MedTech, and consumer heritage.
  • Innovative Medicine holds 28 billion-dollar products, reducing dependence on any single franchise.
  • TREMFYA, Carvykti, and Darzalex give J&J multiple blockbusters beyond STELARA.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-3%
Yahoo Finance
Sep 18th, 2026
J&J stock trades at 28x earnings, but STELARA biosimilar hit distorts valuation

Johnson & Johnson stock has surged 57% over the past year, outpacing the S&P 500's 17% return. Trading at approximately $270 per share, the stock appears expensive at 28.3 times trailing earnings. However, those trailing figures include STELARA, which lost market share to biosimilar competition and reduced operational sales growth by 460 basis points in Q2 2026. Excluding STELARA, the company achieved double-digit growth. The forward outlook looks more attractive, with the stock trading at 24.1 times fiscal 2026 earnings and 20.9 times 2027 estimates. Johnson & Johnson's portfolio includes 28 products generating over $1 billion annually each, with trailing twelve-month revenue near $98 billion. Meanwhile, TREMFYA grew 71% in Q2 2026, becoming the fastest-growing advanced therapy in Crohn's disease and ulcerative colitis. Operating margins improved to 26.8% from a three-year average of 25.7%, supporting expectations for continued margin expansion.

Yahoo Finance
Sep 14th, 2026
Apollo in talks to acquire J&J's orthopedics unit for $20B

Johnson & Johnson shares rose 1.3% in pre-market trading following reports that Apollo Global Management is in discussions to acquire its orthopedics business for approximately $20 billion. Bloomberg News reported the potential deal could be finalised within weeks, citing people familiar with the matter. The orthopedics division generated $9.3 billion in revenue in 2025. However, the business has faced thousands of lawsuits related to its hip replacement devices. No transaction has been confirmed. Investors responded positively to news of the reported discussions and the potential valuation of the orthopedics unit.

Yahoo Finance
Sep 3rd, 2026
J&J rises 1% as AbbVie's myeloma drug shows 74% response rate

Johnson & Johnson shares rose roughly 1% to $277.96 Thursday after AbbVie announced its experimental multiple-myeloma drug, etentamig, achieved a 74% response rate and reduced the risk of disease progression or death by 60% compared to standard therapies. AbbVie's trial positions a convenient monthly treatment in the myeloma market for potential outpatient use. However, J&J is defending its growing franchise, with Carvykti driving 6.8% operational growth in Innovative Medicine during the second quarter. According to Reuters, etentamig appears most differentiated after CAR-T therapy rather than as a direct Carvykti substitute. The market is treating AbbVie's advancement as category expansion rather than a direct threat to J&J. J&J's current share price stands 44.08% above its $192.92 valuation estimate, making future safety and durability data critical for investors.

Yahoo Finance
Sep 1st, 2026
P&G commits $10B in dividends amid 2.8B productivity savings while J&J's 28.5% stock surge masks mid-2027 spinoff risk

Procter & Gamble's dividend strategy is outpacing Johnson & Johnson's despite J&J's stronger stock performance this year. J&J's forward annualised dividend of $5.36 exceeds P&G's $4.354, but its planned mid-2027 DePuy Synthes spinoff threatens its dividend streak. P&G CEO Shailesh Jejurikar committed $10 billion in dividends and $5 billion in buybacks for fiscal 2027, supported by $2.8 billion in productivity savings. The company returned over $15 billion to shareholders in fiscal 2026, including more than $10 billion in dividends. J&J's stock surged 28.5% year-to-date versus P&G's 1.3% gain, driven by strong product performance. However, the upcoming spinoff poses uncertainty, as similar corporate events have disrupted other companies' dividend streaks. P&G faces no such structural risk.

Yahoo Finance
Aug 29th, 2026
J&J stock surges 52.8% in a year, outpacing consumer staples sector with strong pharma growth

Johnson & Johnson has significantly outperformed the consumer staples sector, with shares rising 52.8% over the past 52 weeks compared to the State Street Consumer Staples Select Sector SPDR Fund's 6.5% gain. The New Brunswick-based healthcare giant, valued at $640.5 billion, has seen particularly strong momentum recently, climbing 16.1% over three months. The company's strong performance follows solid second-quarter results released on 15 July, where sales increased 6.6% year-over-year to $25.31 billion. Adjusted earnings per share of $2.90 exceeded market expectations. Johnson & Johnson raised its full-year guidance, projecting adjusted EPS of $11.58 and sales of $101.1 billion. The stock currently trades just 3.1% below its 52-week high of $276.47, reached on 19 August.